Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer May Cut U.S. Sales Force After Cipro Generics Enter Market

Executive Summary

Bayer is looking to make further cuts in its U.S. pharmaceutical division following entry of Cipro generics, Bayer Health Care Chairman Arthur Higgins said during an earnings conference Aug. 3

You may also be interested in...



Bayer U.S. Focus Will Be Oncology, Blood Products And OTCs

Bayer will focus its U.S. pharmaceutical operations on OTCs, oncology and blood products following an agreement giving Schering-Plough marketing rights to its primary care brands

Schering Acquires Levitra Rights From Bayer; Vytorin Launch Is Still Priority

Schering-Plough's acquisition of Bayer's primary care products in the U.S. will not distract the company from the launch of Vytorin, Schering CEO Fred Hassan told investors Sept. 13 at a Bear Stearns conference in New York

Bayer U.S. Focus Will Be Oncology, Blood Products And OTCs

Bayer will focus its U.S. pharmaceutical operations on OTCs, oncology and blood products following an agreement giving Schering-Plough marketing rights to its primary care brands

Related Content

Topics

UsernamePublicRestriction

Register

PS044597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel